Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Research Fellow at Dana-Farber Cancer Institute, shared a post on LinkedIn:
“One week to ESMO25, which will showcase an unprecedented lineup of practice-changing studies.
Seven positive press releases, anticipating the expansion of T-DXd to the curative setting, two Trop2 ADCs reaching first-line mTNBC, 2 novel ET-based combos, adjuvant CDK4/6i improving OS.
So much will change after this conference. Make sure not to miss it.
See you in Berlin!”
More posts featuring Paolo Tarantino on OncoDaily.